Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Discover the latest strategic moves of Duquesne Family Office's $3.72B portfolio, including new stakes, increased investments ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

INDIANAPOLIS (AP) — INDIANAPOLIS (AP) — Eli Lilly and Co. (LLY) on Thursday reported fourth-quarter earnings of $4.41 billion. The Indianapolis-based company said it had profit of $4.88 per share.

Global pharmaceutical company Eli Lilly (NYSE:LLY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue ...

Eli Lilly and Company (NYSE ... Contributing meaningfully to the stock's rise so far this year was the firm’s Q4 2024 earnings report on Feb. 6. Sales of the company’s GLP-1 drugs are still ...

Over the past 12 months, however, it's been Eli Lilly that has been the far better buy, rising more than 17%, while Novo Nordisk's stock has fallen by over 30%. Novo Nordisk Beat Expectations in ...

Lilly has been steadily gaining market share on Novo Nordisk since May 2024. It now controls nearly 49% of the market, while Novo controls 51%. This is a 5% improvement compared to Q4 2023.

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...